Author

D. Zaidman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 4 Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 6 Approach:deep learning· 3 Approach:experimental assay· 2 Assay:protein structure· 2 Approach:statistical model· 2 Organism:mouse· 1 Research Focus:protein structure prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

N. London· 5 shared E. Resnick· 3 shared F. von DelftiD· 2 shared H. Barr· 2 shared A. Aimon· 1 shared A. Bradley· 1 shared A. C. Kotze· 1 shared A. Douangamath· 1 shared

Activity by Year

2018-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersBiochemistry

N. London

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.

D. Zaidman, P. Gehrtz, M. Filep, D. Fearon, J. Prilusky, S. Duberstein, G. Cohen, D. Owen, E. Resnick, C. Strain-Damerell, P. Lukacik, Covid-Moonshot Consortium, H. Barr, M. A. Walsh, F. von Delft, N. London

The paper introduces a computational pipeline to design irreversible inhibitors, identifying a potent SARS-CoV-2 Mpro inhibitor with low micromolar IC50.

Cell Chemical Biology · Dec 1, 2021Peer-reviewedBiochemistry

Conserved interactions required for in vitro inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

A. Shitrit, D. Zaidman, O. Kalid, I. Bloch, D. Doron, T. Yarnizky, I. Buch, I. Segev, E. Ben-Zeev, E. Segev, O. Kobiler

The paper identifies conserved hydrogen-bond interactions in SARS-CoV-2 Mpro and screens FDA-approved drugs to find potential inhibitors.

bioRxiv · Sep 10, 2020Microbiology

PRosettaC: Rosetta based modeling of PROTAC mediated ternary complexes

D. Zaidman, N. London

PRosettaC models PROTAC ternary complexes using Rosetta, achieving near-native predictions and enabling PROTAC design for new targets.

bioRxiv · May 27, 2020Biochemistry

Sulfopin, a selective covalent inhibitor of Pin1, blocks Myc-driven tumor initiation and growth in vivo

C. Dubiella, B. J. Pinch, D. Zaidman, T. D. Manz, E. Poon, S. He, E. Resnick, E. M. Langer, C. J. Daniel, H.-S. Seo, Y. Chen, S. B. Ficarro, Y. Jamin, X. Lian, S. Kibe, , N. London

Sulfopin, a selective Pin1 inhibitor, reduces tumor initiation and growth in neuroblastoma models by targeting c-Myc pathways.

bioRxiv · Mar 20, 2020 · PreprintCancer Biology

Overcoming insecticide resistance through computational inhibitor design

G. Correy, D. Zaidman, A. Harmelin, S. Carvalho, P. D. Mabbitt, V. Calaora, P. J. James, A. C. Kotze, N. London, C. J. Jackson

The paper designs boronic acid inhibitors to overcome insecticide resistance by targeting carboxylesterases in pests, significantly enhancing insecticide efficacy and reducing usage.

bioRxiv · Jan 24, 2019Biochemistry

Rapid covalent-probe discovery by electrophile fragment screening

e. resnick, A. Bradley, J. Gan, A. Douangamath, T. Krojer, R. Sethi, A. Aimon, G. Amitai, D. Belini, J. Bennett, M. Fairhead, O. Fedorov, P. P. Geurink, J. Guo, A. Plotnikov, , N. London

This study develops a method for discovering covalent probes using electrophile fragment screening and identifies selective inhibitors for OTUB2 and NUDT7.

bioRxiv · Oct 14, 2018Biochemistry